- Fesoterodine
drugbox
IUPAC_name = [2- [(1"R")-3-(Di(propan-2-yl)amino)-1-phenylpropyl] -4-(hydroxymethyl)phenyl] 2-methylpropanoate
CAS_number =
CAS_supplemental =
ATC_prefix = G04
ATC_suffix = BD11
ATC_supplemental =
PubChem = 6918558
DrugBank =
C=26 | H=37 | N=1 | O=3
molecular_weight = 411.58 g/mol
bioavailability =
protein_bound =
metabolism =
elimination_half-life =
excretion =
pregnancy_category =
legal_status =
routes_of_administration = Oral
licence_EU = ToviazFesoterodine (INN, brand name Toviaz) is an
antimuscarinic drug developed bySchwarz Pharma AG to treatOveractive bladder syndrome . [cite web| url=http://www.medicalnewstoday.com/articles/41688.php| title=Fesoterodine, New Drug Candidate For Treatment For Overactive Bladder - Pfizer To Acquire Exclusive Worldwide Rights| date=17 April 2006 |publisher=Medical News Today ] It was approved by theEuropean Medicines Agency in April 2007. [cite web| url=http://www.emea.europa.eu/humandocs/Humans/EPAR/toviaz/toviaz.htm| title=Toviaz: European Public Assessment Report, Revision 3 - Published 02/06/08| date=2 June 2008 |publisher=European Medicines Agency ]References
Wikimedia Foundation. 2010.